Drugs / Lung Spheroid Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04262167 | Oct 2020 → Dec 2027 expected | idiopathic pulmonary fibrosis | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lung Spheroid Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04262167 ↗ |
| Modality | Cell therapy | “autologous Lung Spheroid Stem Cells (LSCs)” NCT04262167 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT04262167 ↗ |